An Exploratory Analysis of 5-Alpha Reductase Inhibitors and Risk of Opioid Use Disorder Among Male Medicare Beneficiaries Receiving Prescription Opioid Medications

    Abdelrahman Tawfik, T. Andrew Lister, Ainhoa Gómez-Lumbreras, Randall T. Peterson, Marco Bortolato, Daniel C. Malone
    TLDR Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
    This observational cohort study involving 467,399 male Medicare beneficiaries examined the potential link between 5-alpha reductase inhibitors (5αRIs) and opioid use disorder (OUD) among those prescribed opioids. The study found that 5αRI users had a lower risk of developing OUD, with an adjusted odds ratio of 0.58, and exhibited reduced opioid exposure, as indicated by lower morphine milliequivalents per prescription and fewer opioid claims. While the findings suggest a protective effect of 5αRIs against OUD, the study was exploratory and did not establish a causal relationship. Further research is needed to confirm these results and explore the mechanisms involved, especially in younger and female populations.
    Discuss this study in the Community →

    Research cited in this study

    16 / 16 results